Latest Hotspot

Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707

3 September 2023
5 min read

On August 31, 2023, Sirnaomics announced positive results from Phase 1 clinical trials of its RNAi therapy STP707 for treating various solid tumors. The trial targeted patients suffering from various late-stage solid tumors and unresponsive to standard treatments, with all dosing cohorts now completed. The latest data revealed that about 74% of evaluable patients presented the best response of stable disease (SD), with several patients judged to have reduced tumor load according to the criteria for evaluating the effect of solid tumors. 

STP707 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA, combined and formulated with the carrier of Histidine-Lysine Co-polymer (HKP+H) into nanoparticle preparations. Each individual siRNA possesses the capability of inhibiting the expression of their corresponding target mRNAs. STP707 is also able to simultaneously inhibit the expression of TGF-β1 and COX-2, thereby producing a synergistic effect and reducing inflammations. 

Overexpression of TGF-β1 and COX-2 has been proven to play a key regulatory role in tumor formation. STP707 is designed to leverage its dual-target inhibition properties and Sirnaomics' unique Polymeric Nanoparticle (PNP) introduction technology. By systemic administration, it improves the drug's targeted delivery to solid tumors and metastatic tumors. In a preclinical study of STP707, knockdown of TGF-β1 and COX-2 gene expression was observable in organs including the liver and lungs following intravenous injection. Furthermore, in various preclinical models, STP707 exhibited anti-tumor activity against several types of solid tumors.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The positive results were from a multicenter, open-label, dose escalation, and dose-extension Phase 1 clinical study, carried out by several oncology clinical institutions in the United States. The study examined the safety, tolerability, and antitumor activity of STP707 when administered intravenously. A total of 50 patients with late-stage solid tumors were recruited, including but not limited to pancreatic cancer, liver cancer, colon cancer, ovarian cancer, and melanoma, all of whom had continued to show progressive disease after receiving marketed cancer treatment drugs. This clinical trial was a multicenter, open-label, dose-escalating study evaluating the safety, tolerability, and antitumor activity of STP707. The 50 subjects received doses of 3 mg, 6 mg, 12 mg, 24 mg, 36 mg, and 48 mg via intravenous administration. All patients received one dose per week, with a total of four doses in a 28-day treatment cycle. 

The secondary endpoints of the trial were to determine the pharmacokinetics, biomarkers, and observe preliminary anti-tumor activity of STP707. Based on preliminary efficacy observations, 74% of evaluated subjects achieved the best response of stable disease, and a few patients saw a reduction in their tumor load.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to information disclosed by the synapse database, as of September 1, 2023, there are three drugs under research for COX-2 + TGF-β1 targets, covering 20 indications, being studied by three institutions, involving 11 related clinical trials, and up to 566 patents.

Based on the positive mid-term data of STP707, Sirnaomics plans to explore collaboration for Phase II combination trials, combining STP707 with newly approved cancer therapies (such as immune checkpoint inhibitors) as well as traditional chemotherapy. Potential combination therapies may include cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), melanoma, or pancreatic cancer. The RNAi treatment demonstrates massive potential in treating a variety of diseases, including cancer, diabetes, hepatitis B and specific cardiovascular disorders, looking forward to the performance of STP707 in the field of oncology.

图形用户界面, 文本, 应用程序

描述已自动生成

Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
Latest Hotspot
3 min read
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
3 September 2023
Recently, Neurocrine Biosciences announced new data for the VMAT2 inhibitor drug Ingrezza (valbenazine) capsules, including preliminary results from the Phase III KINECT-HD clinical trial.
Read →
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
SGLT2 Inhibitors - The Cross-Domain Superstar of Antidiabetic Drugs
2 September 2023
SGLT2 inhibitors use a unique insulin-independent mechanism to lower blood glucose levels, not only effectively and safely reducing glucose, but also providing significant cardio-renal protection.
Read →
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
Latest Hotspot
3 min read
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
2 September 2023
Recently, Bristol Myers Squibb has announced the latest long-term follow-up results of two Phase 3 studies that assessed the treatment efficacy of Camzyos (mavacamten).
Read →
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
Latest Hotspot
3 min read
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
2 September 2023
Recently, Roche announced that its PD-L1 targeted antibody, Tecentriq(atezolizumab), has been approved for marketing in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.